Clinical Translation of Targeted α-Therapy: An Evolution or a Revolution?

The Journal of Nuclear Medicine

article

Benedikt Feuerecker¹  Clemens Kratochwil²  Hojjat Ahmadzadehfar³  Alfred Morgenstern⁴  Matthias Eiber¹  Ken Herrmann⁵  Kelsey L. Pomykala⁷ 

[1] Department of Nuclear Medicine, Technische Universität München;Department of Nuclear Medicine, University Hospital Heidelberg;Department of Nuclear Medicine;European Commission, Joint Research Centre;German Cancer Consortium;Department of Nuclear Medicine, University Hospital Essen;Institute for Artificial Intelligence in Medicine, University Hospital Essen

关键词: targeted α-therapy;    α-emitter;    225Ac;    PSMA-617;   

DOI  :  10.2967/jnumed.122.265353

学科分类：医学（综合）

来源: Society of Nuclear Medicine

【 摘 要 】

The field of radioligand therapy has advanced greatly in recent years, driven largely by β-emitting therapies targeting somatostatin receptor–expressing tumors and the prostate-specific membrane antigen. Now, more clinical trials are under way to evaluate α-emitting targeted therapies as potential next-generation theranostics with even higher efficacy due to their high linear energy and short range in human tissues. In this review, we summarize the important studies ranging from the first Food and Drug Administration–approved α-therapy, 223Ra-dichloride, for treatment of bone metastases in castration-resistant prostate cancer, including concepts in clinical translation such as targeted α-peptide receptor radiotherapy and 225Ac-PSMA-617 for treatment of prostate cancer, innovative therapeutic models evaluating new targets, and combination therapies. Targeted α-therapy is one of the most promising fields in novel targeted cancer therapy, with several early- and late-stage clinical trials for neuroendocrine tumors and metastatic prostate cancer already in progress, along with significant interest and investment in additional early-phase studies. Together, these studies will help us understand the short- and long-term toxicity of targeted α-therapy and potentially identify suitable therapeutic combination partners.

【 授权许可】

CC BY